肺腺癌患者PLA2G1B表达情况与预后的相关性  

An Analysis of PLA2G1B Expression and Prognosis in Patients with Lung Adenocarcinoma

作　　者：朱中山[1] 杨洲[1] 江承川 李小兵[1] 任斗[1] 黄橙 张维薇 李湘军 赵顺利[1] ZHU Zhongshan;YANG Zhou;JIANG Chengchuan;LI Xiaobing;REN Dou;HUANG Cheng;ZHANG Weiwei;LI Xiangjun;ZHAO Shunli(Dept.of Oncology,The 2nd People’s Hospital of Hunan,Changsha Hunan 410007,China)

机构地区：[1]湖南省第二人民医院肿瘤科,湖南长沙410007

出　　处：《昆明医科大学学报》2022年第9期70-76,共7页Journal of Kunming Medical University

基　　金：湖南省自然科学基金科卫联合基金资助项目(2020JJ8080);湖南省脑科医院院级基金资助项目(2017B09,2018B01,2018B14)。

摘　　要：目的基于数据挖掘分析PLA2G1B基因在肺腺癌患者中的表达特征、预后特征、免疫特征以及潜在的治疗方案影响。方法通过对TCGA以及GEO数据库中的肺腺癌患者RNAseq表达谱数据以及临床信息进行分析,对比PLA2G1B高表达和低表达在肺腺癌患者的预后差异,并通过CIBERSORT计算患者的免疫细胞浸润程度,对比PLA2G1B高低表达组之间的浸润程度差异。并通过p RRophetic算法分析2组之间的药物敏感性差异。结果PLA2G1B基因在肺腺癌组织中相比癌旁表达量显著降低,且表达量越低其患者的预后总生存越差,在TCGA以及2个GEO的独立验证数据集中均表现出一致的统计学差异,经多因素校正之后证明PLA2G1B低表达为差预后的独立因素(P<0.05),且在预后较差的样本中其免疫浸润水平更低,主要表现为Bcellmemory,Tcell CD4+memoryresting,Monocyte,Myeloiddendriticcell,Mastcellactivated细胞类型。但差预后的样本对多种化疗药物的敏感性要显著更好。结论PLA2G1B低表达为肺腺癌独立的差预后风险因素,且低表达患者中整体免疫浸润水平显著更低。Objective To analyze PLA2G1B gene expression,prognosis,immunologic features and potential therapeutic effects in patients with lung adenocarcinoma,based on the data-mining of public databases.Methods Data from TCGA and GEO database of LUAD were collected,including gene expression matrix and clinical data.The overall survival(OS)rate was compared between these two groups of PLA2G1B high expressed and low expressed.CIBERSORT algorithm was introduced to calculate totally 22 immune cells infiltration level and their difference was also compared between PLA2G1B high and low groups.Finally,pRRophetic was used to find some drugs that were probably sensitive to the worse OS groups.Results PLA2G1B was down regulated in LUAD samples and the lower expression of PLA2G1B led to a worse OS in LUAD,this result was validated in two independent GEO cohorts.After adjusting three main clinical elements,PLA2G1B was proved to be an independent prognosis biomarker(P<0.05).For the worse OS group,we also found its immune infiltration level was lower than the better OS group,especially for B cell memory,T cell CD4+memory resting,Monocyte,Myeloid dendritic cell and Mast activated cells.For the worse OS group,we found they might be more sensitive to several chemo drugs including Cisplatin,Docetaxel,Etoposide,Gemcitabine,Paclitaxeland Vinorelbine.Conclusion PLAG21B is an independent prognosis biomarker in LUAD and the ones low expressed showed worse OS and lower immune infiltration level.

关 键 词：肺腺癌 PLA2G1B 预后 数据挖掘 免疫浸润 

分 类 号：R734[医药卫生—肿瘤]